A Race Against Time:the Challenge of Cardiovascular Disease in Developing Economies
by: Stephen Leeder, Susan Raymond, Henry Greenberg, Hui Liu, Kathy Esson
A Race Against Time:the Challenge of Cardiovascular Disease in Developing Economies
By Stephen Leeder, Susan Raymond, Henry Greenberg, Hui Liu, Kathy Esson
Publisher: The Australian Health Policy Institute at the University of Sydney
The Initiative for Cardiovascular Health Research in The Developing Countries
Mailman School of Public Health
The Earth Institute at Columbia University
Number Of Pages: 108
Publication Date: 2003
ISBN-10 / ASIN: 0975433601
ISBN-13 / EAN: 9780975433607
Product Description:
This report derives from a project conducted at Columbia University during 2003, which examined the economic and social consequences of cardiovascular disease in developing economies. The project followed on from the work of the commission on macroeconomics and health, chaired by professor Jeffrey Sachs.
The Report of the World Health Organization (WHO) Commission on Macroeconomics and Health (CMH) in 2001 called attention to the two-way causation between health and economic development. Investments in health not only reduce the burden of disease, but also stimulate economic growth, which in turn raises a society’s ability to invest in public health. On the other hand, when an economy is too impoverished to invest in health, it is likely to experience a devastating downward spiral of rising disease burden and deepening poverty. The CMH focused much of its attention on the urgent public health crises of sub-Saharan Africa, a region ravaged by HIV, malaria and tuberculosis. It did note, however, that cardiovascular deaths were set to increase from 3 million in 1998 to almost 5 million in 2020 in the WHO Demographically Developing Regions (without interventions), a year in which the number of deaths from infectious diseases and related conditions would equal the number of deaths due to chronic diseases. A central message of the CMH Report was that scaling up the investment in health, both from the resources available within a country, and with foreign aid when needed, was vital to enable the world’s poorest places to escape from the trap of extreme poverty.
Contents:
Cover
Title Page
Contents
Forewords
Definitions and abbreviations used in this report
Definitions
Abbreviations
Introduction
A-1. Origins and rationale of this report
The global signifcance of cardiovascular disease
B-1. What are the global data?
CVD status and projections in five developing countries
C-1. Methods and demographic profiles
C-2. Overall CVD experience in the five study and two comparator countries
C-3. Labor force implications
C-3a. Mortality concentration in people of working age
C-3b. Workforce CVD mortality projections to 2030
C-3c. Higher morbidity in working ages
C-3d. CVD and women’s health
C-3e. Widowhood
C-3f. What will happen if CVD risk factors get better or worse?
The macroeconomic and economic consequences of CVD
D-1. Years of potentially productive life lost
D-2 Disability adjusted life years lost
D-3. Disability
D-4. Direct health care costs
D-5. Household viability and dependency
Intervention strategies to reduce the impact of CVD
E-1. Levels of prevention of CVDBroadly
E-1a. Macro economic and whole-of-government interventions that affect everyone4
E-1b. Population-based interventions
E-1c. Provider-based prevention
E-2a. The costs of clinic-based risk factor interventions
E-2. Practicalities of CVD prevention
From analysis to action
F-1. The socio-political context: instituting change in civil societies
F-2. CVD as a macroeconomic challen
F-2a. Who should be at the table?
F-2b. What should be on the agenda?
F-2c. What resource pools do national leaders need to mobilize?
Conclusions
G-1. Putting CVD in the developing world on the international health and development agenda
G-2. Deeper documentation of the prevalence and costs of CVD
G-3. Developing partnerships at the macroeconomic level with national governments in key developing countries
G-4. Train the trainer initiatives in health education
G-5. Undertaking trial treatment and prevention interventions
G-6. Longer term research and interventions
Acknowledgements
References
Back Cover
Please Login or Register to read the rest of this content.
Related Posts
- Advances in Pharmacology Volume 31 Anesthesia and Cardiovascular Disease